Pharma Phoes: Medtechs that could bust drugs
This article was originally published in Clinica
Everyone wants to be able to pop a magic pill and see their ills melt away. No risky surgery, no unsightly scars, no painful recuperation. Yet, the tide looks to be changing, as advances in medical technology mean that surgical intervention is becoming increasingly less invasive or, in some cases, completely noninvasive. Many of these medtech alternatives not only offer a one-time solution that could take patients off the hamster wheel of never-ending medications, but also attractive cost savings to healthcare payers.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.